Rociletinib/Osimertinib for EGFR T790M-negative NSCLC episode artwork

EPISODE · Apr 20, 2016 · 5 MIN

Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

from GRACEcast · host cancerGRACE Meetings

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

Episode metadata supplied by the publisher feed · Published Apr 20, 2016

Embed this episode

NOW PLAYING

Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

0:00 5:20

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 5 minutes long.

When was this GRACEcast episode published?

This episode was published on April 20, 2016.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!